Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...

Researchers from PMV Pharmaceuticals Inc. and collaborators described the effect of rezatapopt (PC-14586), a first-in-class selective p53 reactivator designed to reinstate p53 Y220C mutant function.

FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability challenges of non-covalent approaches In preclinical studies, FMC-220 demonstrated ...

New Drug Research & Development Co. Ltd. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.

It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. Receive News & Ratings for PMV ...

Association between proto-oncogene N-RAS transcript level and overall survival in node-negative muscle-invasive urothelial bladder carcinoma.

No one really understands why activation of the tumor suppressor p53 sometimes leads to cell-cycle arrest and sometimes induces an apoptotic program. It has been proposed that post-translational ...

The ATM gene (mutated in the disease ataxia telangiectasia) activates the p53 tumor suppressor protein in response to DNA damage, explaining the higher incidence of cancer in AT patients.

The paper titled,“Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development” can be accessed here . Announced a partnership with ...